Neuropeptides
Selank
A synthetic tuftsin-related heptapeptide.
- Evidence
- Early clinical
- Literature
- Experimental and limited clinical literature
- Family
- Tuftsin-related neuropeptide
Overview
Selank appears in experimental literature concerning neural, immune, and stress-related signaling. Human evidence is limited, and broad consumer claims extend well beyond what the published record can establish.
Evidence maturity
Early human evidence
The score summarizes evidence maturity, not safety, effectiveness, or suitability for any use.
Mechanism summary
Investigated in neurochemical, stress-response, and immune-neural signaling models.
- Research category
- Cognitive Function
- Editorial status
- Published
Evidence synthesis
Structured evidence summary
- Human studies
- 2
- Animal studies
- 8
- In vitro records
- 1
- Review records
- 5
- Abstract extracted
- 5
- Metadata verified
- 11
Evidence strength
Limited translational
Confidence
Low confidence
Major findings
- The verified set includes human anxiety-comparison records plus animal and cell-context publications involving stress, GABAergic, inflammation-related, and hepatocyte or gastric-mucosa models.
- A shared Semax/Selank connectomic publication supports internal comparison routing but does not establish interchangeability.
Major limitations
- The literature is heterogeneous across model systems, and many records require deeper extraction before endpoint-level synthesis.
- Safety coverage remains incomplete and explicitly review-required.
Counts are generated from verified PubMed records. Findings above are evidence-map observations, not clinical recommendations or inferred study outcomes. See the scoring methodology.
Scoring methodology
Evidence strength, quality, and confidence
Evidence strength
Compound-level strength is based on the verified study mix: human records, animal records, review or synthesis records, and extraction depth. It describes evidence maturity only.
Study quality
Study-level quality is not assessed for metadata-only records. Abstract-extracted records are rated from study design and extraction depth, not from unreviewed full-text claims.
Confidence
Confidence is capped when records remain metadata verified. Atlas does not raise confidence by counting citations without extracting endpoints, comparators, duration, and limitations.
Workflow states are `METADATA_VERIFIED`, `ABSTRACT_EXTRACTED`, `FULLTEXT_REVIEWED`, and `EDITORIAL_APPROVED`. Because full-text review is not available in this phase, no study is promoted to full-text or editorial-approved status.
Research timeline
Evidence stages describe maturity, not a chronological promise of development.
Identity and target
DocumentedThe compound identity or proposed target is described in research literature.
Preclinical research
DocumentedLaboratory or animal research forms part of the evidence base.
Human research
EmergingSome human research exists, but scope or maturity remains limited.
Independent synthesis
LimitedIndependent replication and synthesis remain important evidence gaps.
Open research questions
- 01How reproducible are reported neurochemical effects?
- 02What is known about pharmacokinetics in humans?
- 03How should immune and neural findings be integrated?
Literature starting points
These links support further review; inclusion is not an endorsement of every indexed conclusion.
- 01Open source
Selank literature index
PubMed, U.S. National Library of Medicine · Database
- 02Open source
Atlas internal research database
Internal Research Database · 2026 · Database
Phase 2 study database
16 verified publications
Deep research cluster
Explore Selank by evidence question
Related comparisons
Continue the research map